Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-targeting HER2/PD-L1 CAR-T in HER2+ Solid Tumors
NCT04684459Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dual-targeting HER2 and PD-L1 CAR-T cells in HER2-positive solid tumor, sponsored by Sichuan University. Primary endpoints: Incidence of Treatment-Related Adverse Events at 12 months and Dose-limiting toxicity at 12 months. Started Mar 2021; status: recruiting.
02
Drugs
dual-targeting HER2 and PD-L1 CAR-T cells
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04684459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684459.